0000950170-24-099982.txt : 20240822
0000950170-24-099982.hdr.sgml : 20240822
20240822192358
ACCESSION NUMBER: 0000950170-24-099982
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240821
FILED AS OF DATE: 20240822
DATE AS OF CHANGE: 20240822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lian Brian
CENTRAL INDEX KEY: 0001614578
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 241233187
MAIL ADDRESS:
STREET 1: C/O SEELOS THERAPEUTICS, INC.
STREET 2: 300 PARK AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-08-21
0001607678
Viking Therapeutics, Inc.
VKTX
0001614578
Lian Brian
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
true
true
false
false
President & CEO
true
Common Stock, par value $0.00001 per share
2024-08-21
4
M
false
1000
7.77
A
2355927
D
Common Stock, par value $0.00001 per share
2024-08-21
4
S
false
1000
69.90
D
2354927
D
Stock Option (Right to Buy)
7.77
2024-08-21
4
M
false
1000
0
D
2021-01-03
2030-01-03
Common Stock
1000
231130
D
The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person.
25% of the shares subject to the option vested on each anniversary of the grant date.
/s/ Michael Morneau, as Attorney-in-Fact
2024-08-22